Catalyst Pharmaceuticals (Nasdaq:CPRX) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CPRX Panoramica delle azioni

Catalyst Pharmaceuticals, Inc. è un'azienda biofarmaceutica in fase di sviluppo commerciale che si concentra sullo sviluppo e la commercializzazione di terapie per persone affette da malattie rare debilitanti, croniche, neuromuscolari e neurologiche negli Stati Uniti.

Informazioni sull'azienda

CPRX analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	5/6
Prestazioni passate	2/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 70% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 20.89% all'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 50.8%

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Importanti vendite da parte di insider negli ultimi 3 mesi

I margini di profitto (15.7%) sono inferiori rispetto allo scorso anno (38.1%)

Catalyst Pharmaceuticals, Inc. Concorrenti

MannKind

NasdaqGM:MNKD

US$1.4b

ACADIA Pharmaceuticals

NasdaqGS:ACAD

US$2.6b

ADMA Biologics

NasdaqGM:ADMA

US$4.1b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Catalyst Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$19.99
Massimo di 52 settimane	US$20.31
Minimo di 52 settimane	US$11.55
Beta	0.70
1Variazione di 1 mese	18.00%
Variazione a 3 mesi	20.93%
Variazione di 1 anno	36.92%
3Variazione a 3 anni	250.70%
Variazione a 5 anni	243.47%
Variazione dall'IPO	227.70%

Notizie e aggiornamenti recenti

Recent updates

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jul 24

Catalyst Pharmaceuticals: New Products In Proving Phase

Jul 06

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Apr 06

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jan 29

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Jan 17

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Sep 06

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

May 27

Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?

Feb 13

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?

Nov 11

Rendimenti per gli azionisti

	CPRX	US Biotechs	US Mercato
7D	3.6%	5.3%	4.9%
1Y	36.9%	15.7%	25.6%

Ritorno vs Industria: CPRX ha superato il US Biotechs che ha restituito 15.7 % nell'ultimo anno.

Rendimento vs Mercato: CPRX ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is CPRX's price volatile compared to industry and market?
CPRX volatility
CPRX Average Weekly Movement	5.9%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: Il prezzo delle azioni di CPRX è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di CPRX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	167	Rich Daly	www.catalystpharma.com

Catalyst Pharmaceuticals, Inc. è un'azienda biofarmaceutica in fase di sviluppo commerciale che si concentra sullo sviluppo e la commercializzazione negli Stati Uniti di terapie per persone affette da malattie rare debilitanti, croniche, neuromuscolari e neurologiche. L'azienda offre Firdapse, un farmaco a base di amifampridina fosfato in compresse per il trattamento di pazienti affetti da sindrome miastenica di Lambert-Eaton (LEMS), e Ruzurgi per il trattamento di pazienti pediatrici affetti da LEMS. L'azienda sviluppa Firdapse per il trattamento della miastenia gravis positiva agli anticorpi MuSK e dell'atrofia muscolare spinale.

Catalyst Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Catalyst Pharmaceuticals con la sua capitalizzazione di mercato?
CPRX statistiche fondamentali
Capitalizzazione di mercato	US$2.36b
Guadagni(TTM)	US$68.15m
Ricavi(TTM)	US$434.48m

34.8x

Rapporto P/E

5.5x

Rapporto P/S

CPRX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CPRX Conto economico (TTM)
Ricavi	US$434.48m
Costo del fatturato	US$151.27m
Profitto lordo	US$283.20m
Altre spese	US$215.05m
Guadagni	US$68.15m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.57
Margine lordo	65.18%
Margine di profitto netto	15.69%
Rapporto debito/patrimonio netto	0%

Come si è comportato CPRX nel lungo periodo?

Vedi performance storica e confronto

CPRX Panoramica delle azioni

Premi

Analisi del rischio

Catalyst Pharmaceuticals, Inc. Concorrenti

NasdaqGM:MNKD

US$1.4b

NasdaqGS:ACAD

US$2.6b

NasdaqGM:ADMA

US$4.1b

NasdaqGM:PTGX

US$2.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Recent updates

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 16%

Chief Medical & Regulatory Officer notifies of intention to sell stock

Price target increased by 8.4% to US$29.57

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Revises Revenue Guidance for the Full-Year 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Catalyst Pharmaceuticals: New Products In Proving Phase

Chief Medical & Regulatory Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Catalyst Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Catalyst Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

Independent Director notifies of intention to sell stock

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

Insider recently sold US$411k worth of stock

Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (Dmd)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024

Catalyst Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

Catalyst Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Co-Founder exercised options to buy US$4.3m worth of stock.

Investor sentiment improves as stock rises 15%

Price target increased by 13% to US$26.20

Catalyst Pharmaceuticals, Inc. Announces Firapse New Drug Application Submitted in Japan by Partner DyDo Pharma

COO & Chief Scientific Officer recently sold US$570k worth of stock

COO & Chief Scientific Officer notifies of intention to sell stock

Catalyst Pharmaceuticals, Inc. Appoints Michael W. Kalb as Its Chief Financial Officer, Effective on January 1, 2024

Catalyst Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Receives Two New U.S. Patent Allowances for FIRDAPSE

Catalyst Pharmaceuticals, Inc. Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals

Catalyst Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Catalyst Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Consensus EPS estimates fall by 17%

Catalyst Pharmaceuticals, Inc. Announces FDA Acceptance of the Supplemental New Drug Application for Firapse

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case

Catalyst Pharmaceuticals, Inc. Announces the Resignation of Philip H. Coelho as Independent Member of the Board

Catalyst Pharmaceuticals, Inc. Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to Be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Second quarter 2023 earnings released: EPS: US$0.35 (vs US$0.21 in 2Q 2022)

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2023

Catalyst Pharmaceuticals, Inc. Announces Resignation of Patrick J. Mcenany as Chief Executive Officer

Catalyst Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Catalyst Pharmaceuticals, Inc., Annual General Meeting, Aug 22, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?

Consensus EPS estimates fall by 23%

Investor sentiment deteriorates as stock falls 28%

COO & Chief Scientific Officer exercised options to buy US$1.3m worth of stock.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2023

Catalyst Pharmaceuticals, Inc. Advances sNDA Submission Plans to Increase Indicated Maximum Dose for FIRDAPSE®? from 80 Mg Per Day to 100 Mg Per Day

Independent Director exercised options and sold US$481k worth of stock

Insider exercised options and sold US$747k worth of stock